{"id":"https://openalex.org/W2133644259","doi":"https://doi.org/10.1093/rheumatology/keu269.052","title":"Is the comparitive restriction of biologic use in children and adolescents justified at the service level: a comparison with adult use","display_name":"Is the comparitive restriction of biologic use in children and adolescents justified at the service level: a comparison with adult use","publication_year":2014,"publication_date":"2014-08-23","ids":{"openalex":"https://openalex.org/W2133644259","doi":"https://doi.org/10.1093/rheumatology/keu269.052","mag":"2133644259"},"language":"en","primary_location":{"id":"doi:10.1093/rheumatology/keu269.052","doi":"https://doi.org/10.1093/rheumatology/keu269.052","is_oa":false,"landing_page_url":"https://doi.org/10.1093/rheumatology/keu269.052","pdf_url":null,"source":{"id":"https://openalex.org/S183989336","display_name":"Lara D. Veeken","issn_l":"1462-0324","issn":["1462-0324","1462-0332"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Rheumatology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5111665614","display_name":"Nina Wilkinson","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"N. Wilkinson","raw_affiliation_strings":["Oxford Paediatric and Adolescent Rheumatology Centre, Oxford, UK","1Oxford Paediatric and Adolescent Rheumatology Centre, Oxford, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oxford Paediatric and Adolescent Rheumatology Centre, Oxford, UK","institution_ids":[]},{"raw_affiliation_string":"1Oxford Paediatric and Adolescent Rheumatology Centre, Oxford, UK","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069965130","display_name":"Rebecca E. Waller","orcid":"https://orcid.org/0000-0002-5069-1183","observed_orcids":["https://orcid.org/0000-0002-5069-1183"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. Waller","raw_affiliation_strings":["Oxford Paediatric and Adolescent Rheumatology Centre, Oxford, UK","1Oxford Paediatric and Adolescent Rheumatology Centre, Oxford, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oxford Paediatric and Adolescent Rheumatology Centre, Oxford, UK","institution_ids":[]},{"raw_affiliation_string":"1Oxford Paediatric and Adolescent Rheumatology Centre, Oxford, UK","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015504392","display_name":"Anwar E. Ahmed","orcid":"https://orcid.org/0000-0001-8743-6007","observed_orcids":["https://orcid.org/0000-0001-8743-6007"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Ahmed","raw_affiliation_strings":["Oxford Paediatric and Adolescent Rheumatology Centre, Oxford, UK","1Oxford Paediatric and Adolescent Rheumatology Centre, Oxford, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oxford Paediatric and Adolescent Rheumatology Centre, Oxford, UK","institution_ids":[]},{"raw_affiliation_string":"1Oxford Paediatric and Adolescent Rheumatology Centre, Oxford, UK","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5013118324","display_name":"Eunice Godbold","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"E. Godbold","raw_affiliation_strings":["Oxford Paediatric and Adolescent Rheumatology Centre, Oxford, UK","1Oxford Paediatric and Adolescent Rheumatology Centre, Oxford, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oxford Paediatric and Adolescent Rheumatology Centre, Oxford, UK","institution_ids":[]},{"raw_affiliation_string":"1Oxford Paediatric and Adolescent Rheumatology Centre, Oxford, UK","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3486,"currency":"GBP","value_usd":4597},"apc_paid":null,"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.1508699,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11616","display_name":"Autoimmune and Inflammatory Disorders Research","score":0.9502000212669373,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11616","display_name":"Autoimmune and Inflammatory Disorders Research","score":0.9502000212669373,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":0.03700000047683716,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.0015999999595806003,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/biologic-agents","display_name":"biologic agents","score":0.7089999914169312},{"id":"https://openalex.org/keywords/juvenile-idiopathic-arthritis","display_name":"juvenile idiopathic arthritis","score":0.824999988079071},{"id":"https://openalex.org/keywords/pediatric-rheumatology","display_name":"pediatric rheumatology","score":0.703000009059906},{"id":"https://openalex.org/keywords/nice-approval","display_name":"NICE approval","score":0.6079999804496765},{"id":"https://openalex.org/keywords/treatment-efficacy","display_name":"treatment efficacy","score":0.460999995470047},{"id":"https://openalex.org/keywords/treatment-tolerability","display_name":"treatment tolerability","score":0.6349999904632568},{"id":"https://openalex.org/keywords/cost-comparison","display_name":"cost comparison","score":0.453000009059906},{"id":"https://openalex.org/keywords/adalimumab","display_name":"adalimumab","score":0.7540000081062317},{"id":"https://openalex.org/keywords/infliximab","display_name":"infliximab","score":0.9950000047683716},{"id":"https://openalex.org/keywords/anakinra","display_name":"anakinra","score":0.9919999837875366},{"id":"https://openalex.org/keywords/treatment-withdrawal","display_name":"treatment withdrawal","score":0.42399999499320984},{"id":"https://openalex.org/keywords/remission","display_name":"remission","score":0.6779999732971191},{"id":"https://openalex.org/keywords/uveitis","display_name":"uveitis","score":0.5690000057220459}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9411091208457947},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.3304465413093567},{"id":"https://openalex.org/C512399662","wikidata":"https://www.wikidata.org/wiki/Q3505712","display_name":"Family medicine","level":1,"score":0.32156550884246826}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1093/rheumatology/keu269.052","doi":"https://doi.org/10.1093/rheumatology/keu269.052","is_oa":false,"landing_page_url":"https://doi.org/10.1093/rheumatology/keu269.052","pdf_url":null,"source":{"id":"https://openalex.org/S183989336","display_name":"Lara D. Veeken","issn_l":"1462-0324","issn":["1462-0324","1462-0332"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Rheumatology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1740877651","https://openalex.org/W2416960225","https://openalex.org/W2145180518","https://openalex.org/W2520597985","https://openalex.org/W2553783688","https://openalex.org/W4226059506","https://openalex.org/W2053358474","https://openalex.org/W4413185185","https://openalex.org/W3017758724","https://openalex.org/W51725030"],"abstract_inverted_index":{"Introduction:":[0],"Whereas":[1],"routine":[2,30],"treatment":[3,154],"of":[4,41,59,64,145,149,153,190],"inflammatory":[5],"arthritis":[6],"in":[7,46,54,143,188],"adults":[8],"includes":[9],"eight":[10],"biologic":[11,52,77],"agents":[12,27,177],"with":[13,51,107,186],"grounds":[14],"for":[15,81,151],"sequential":[16,31],"use,":[17],"children":[18],"and":[19,28,39,43,48,70,141],"young":[20],"persons":[21],"(CYP)":[22],"are":[23],"confined":[24],"to":[25,104],"two":[26],"no":[29,137],"use.":[32],"Aims:":[33],"To":[34],"compare":[35,49],"service-level":[36],"efficacy,":[37],"tolerability":[38],"costs":[40],"NICE":[42],"non-NICE-approved":[44],"biologics":[45],"CYP":[47,82],"this":[50],"use":[53],"adults.":[55],"Method:":[56],"Retrospective":[57],"analysis":[58],"6-year":[60],"data":[61],"from":[62,174],"databases":[63],"a":[65],"regional":[66],"paediatric":[67],"rheumatology":[68],"service":[69],"the":[71,116],"local":[72],"adult":[73],"service.":[74],"Results:":[75],"197":[76],"prescriptions":[78,113],"were":[79,103,114,136,178,183],"made":[80],"(mean":[83],"age":[84,144],"12.3":[85],"years":[86],"(range":[87],"1.4\u201320.6":[88],"years);":[89],"mean":[90],"duration":[91],"23":[92],"months":[93],"(3\u2013110":[94],"months);":[95],"total":[96],"366":[97],"patient":[98],"years).":[99],"Of":[100],"these":[101],"173":[102],"121":[105],"patients":[106],"JIA":[108],"or":[109,147,163],"associated":[110],"uveitis.":[111],"64":[112],"NICE-approved;":[115],"rest":[117],"(adalimumab":[118],"62,":[119],"Infliximab":[120],"21,":[121],"golimumab":[122],"4,":[123],"anakinra":[124,187],"10,":[125],"tocilizumab":[126],"3,":[127],"abatacept":[128],"5,":[129],"rituximab":[130],"2)":[131],"required":[132],"individual":[133],"funding.":[134],"There":[135,182],"differences":[138,173],"between":[139],"non-NICE":[140,176],"NICE-agents":[142],"onset,":[146],"rates":[148],"withdrawal":[150],"failure":[152],"(P":[155,160,165],"=":[156,161,166],"0.89),":[157],"adverse":[158],"events":[159],"0.64),":[162],"remission":[164],"0.72)":[167],"(Table":[168],"1).":[169],"In":[170],"general,":[171],"cost":[172],"using":[175],"minor,":[179],"except":[180],"infliximab.":[181],"significant":[184],"savings":[185],"6":[189],"9":[191],"SoJIA-patients.":[192]},"counts_by_year":[],"updated_date":"2026-10-29T09:56:32.521200","created_date":"2016-06-24T00:00:00"}